Following a story · 2 updates
Curium to acquire Lantheus for up to 8 billion dollars
Aug 3, 2026 – Aug 5, 2026
-
Curium to acquire Lantheus in $8 billion radiopharma merger
Curium agreed to pay Lantheus shareholders up to $114.50 a share, $102.50 in cash plus up to $12 in contingent value rights tied to sales milestones through 2030, in a deal expected to close in the first half of 2027.
Read this issue → -
Curium to acquire Lantheus for up to 8 billion dollars
Curium agreed August 3, 2026 to buy Lantheus Holdings for 102.50 dollars per share cash plus a contingent value right worth up to 12.00 dollars per share, up to 114.50 dollars per share total, in the largest radiopharmaceutical deal ever.
Read this issue →